WAT Stock Recent News
WAT LATEST HEADLINES
MILFORD, Mass., Dec. 21, 2023 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra Ph.D.
Waters (WAT) reported earnings 30 days ago. What's next for the stock?
MILFORD, Mass. , Nov. 16, 2023 /PRNewswire/ -- Waters Corporation (NYSE: WAT) announced that Udit Batra Ph.D.
Waters' (WAT) Q3 results benefit from a strong Pharmaceutical market, as well as a strong contribution from the Wyatt acquisition.
Waters Corporation (NYSE:WAT ) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Caspar Tudor – Head-Investor Relations Udit Batra – President and Chief Executive Officer Amol Chaubal – Senior Vice President and Chief Financial Officer Conference Call Participants Vijay Kumar – Evercore ISI Dan Brennan – TD Cowen Matt Sykes – Goldman Sachs Derik De Bruin – Bank of America Rachel Vatnsdal – JPMorgan Eve Burstein – Bernstein Research Operator Good morning. Welcome to the Waters Corporation Third Quarter 2023 Financial Results Conference Call.
Evaluate the expected performance of Waters (WAT) for the quarter ended September 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Waters' (WAT) third-quarter 2023 results are likely to reflect strength in liquid chromatography instruments and mass spectrometers amid uncertainties in the global economy.
Waters (WAT) partners with the University of San Agustin to provide the latter with technology equipment in its newly developed mass spectrometry imaging center in the Philippines.
Waters Corporation has pushed lower into H2 FY'23, in continuation of the longer-term downtrend. WAT's acquisition of Wyatt Technology was a large premium that to me signaled a lack of profitable investment runway. Despite exceptional returns on existing capital, the incremental returns don't match these numbers, clamping earnings and FCF growth.
Waters Corporation has seen a significant hit to its share price as momentum has left the life sciences tools space and as spending from the key biopharma end-market has corrected. Biopharma spending likely won't return to the torrid pace of the boom years, but ongoing investments into discovery tools, production equipment, and QA/QC equipment should drive healthy growth. The company's presence in industrial markets, such as food and water quality testing, provides a steady source of profitability and growth potential in areas like battery testing and sustainable polymers.